PBOX-15 Induces Apoptosis in Multiple Myeloma
Author Information
Author(s): Maginn E N, Browne P V, Hayden P, Vandenberghe E, MacDonagh B, Evans P, Goodyer M, Tewari P, Campiani G, Butini S, Williams D C, Zisterer D M, Lawler M P, McElligott A M
Primary Institution: John Durkan Leukaemia Laboratories, Institute of Molecular Medicine, Trinity College Dublin, St James's Hospital, Dublin, Ireland
Hypothesis
PBOX-15, a novel microtubule-targeting agent, induces apoptosis in multiple myeloma cells.
Conclusion
PBOX-15 induces apoptosis and potentiates TRAIL-induced cell death in multiple myeloma cells.
Supporting Evidence
- PBOX-15 induced apoptosis in ex vivo myeloma cells and in myeloma cell lines.
- Death receptor genes were upregulated in myeloma cells treated with PBOX-15.
- Caspase-8 was identified as a key mediator in PBOX-15-induced apoptosis.
- PBOX-15 treatment resulted in significant apoptosis in patient-derived myeloma cells.
- Combination treatment with PBOX-15 and TRAIL significantly increased apoptosis.
Takeaway
PBOX-15 is a new drug that helps kill cancer cells in multiple myeloma, a type of blood cancer, by making them die faster.
Methodology
The study assessed the anti-myeloma activity of PBOX-15 using various myeloma cell lines and primary myeloma cells, analyzing apoptosis and gene expression through flow cytometry and western blot analysis.
Limitations
The study primarily focused on in vitro and ex vivo models, which may not fully represent in vivo responses.
Participant Demographics
Five myeloma patients, including newly diagnosed and treatment naive individuals, as well as a relapsed patient.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website